公开(公告)号：US20190183979A1

公开(公告)日：2019-06-20

申请号：US16280603

申请日：2019-02-20

申请人： Novo Nordisk A/S

发明人： Mathias Norrman ,  Susanne Hostrup ,  Dorte Bjerre Steensgaard ,  Holger Martin Strauss ,  Rosa Rebecca Erritzoee Hansen ,  Svend Havelund ,  Morten Schlein ,  Jesper Soendergaard Pedersen

IPC分类号： A61K38/28 ,  A61K47/02 ,  A61K47/10 ,  A61P5/48

摘要： The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.

公开(公告)号：US20150182595A1

公开(公告)日：2015-07-02

申请号：US14658358

申请日：2015-03-16

申请人： Novo Nordisk A/S

发明人： Helle Birk Olsen ,  Svend Havelund ,  Ulla Ribel-Madsen ,  Jeppe Sturis ,  Helle Naver ,  Morten Schlein ,  Svend Ludvigsen

IPC分类号： A61K38/28 ,  A61K47/18 ,  A61K31/455

CPC分类号： A61K38/28 ,  A61K9/0019 ,  A61K31/198 ,  A61K31/455 ,  A61K31/465 ,  A61K45/06 ,  A61K47/02 ,  A61K47/183 ,  A61K47/22 ,  A61K2300/00

摘要： Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid.

摘要翻译： 包含胰岛素化合物或两种或更多种胰岛素化合物，烟碱化合物和氨基酸的混合物的胰岛素制剂。

公开(公告)号：US20220202909A1

公开(公告)日：2022-06-30

申请号：US17692238

申请日：2022-03-11

申请人： Novo Nordisk A/S

发明人： Mathias Norrman ,  Susanne Hostrup ,  Dorte Bjerre Steensgaard ,  Holger Martin Strauss ,  Rosa Rebecca Erritzoee Hansen ,  Svend Havelund ,  Morten Schlein ,  Jesper Soendergaard Pedersen

IPC分类号： A61K38/28 ,  A61P5/48 ,  A61K47/02 ,  A61K47/10

摘要： The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.

公开(公告)号：US20140349925A1

公开(公告)日：2014-11-27

申请号：US14453276

申请日：2014-08-06

申请人： Novo Nordisk A/S

发明人： Ib Jonassen ,  Thomas Hoeg-Jensen ,  Svend Havelund ,  Ulla Ribel-Madsen ,  Tina Moeller Tagmose ,  Peter Madsen

IPC分类号： C07K14/62

CPC分类号： C07K14/62 ,  A61K38/28 ,  A61K47/542

摘要： The present invention relates to insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the α-amino group of the N-terminal amino acid residue of the B chain or to the ε-amino group of a Lys residue present in the B chain of the parent insulin, the side chain being of the general formula: —W—X—Y—Z wherein W, X, Y and Z are as defined in the disclosure.

摘要翻译： 本发明涉及胰岛素衍生物，其是天然存在的胰岛素或其类似物，其具有侧链连接到B链的N-末端氨基酸残基的α-氨基或与α-链氨基的氨基 存在于母体胰岛素的B链中的Lys残基，侧链具有以下通式：-W-X-Y-Z，其中W，X，Y和Z如本公开中所定义。

公开(公告)号：US20140206610A1

公开(公告)日：2014-07-24

申请号：US14223408

申请日：2014-03-24

申请人： Novo Nordisk A/S

发明人： Helle Birk Olsen ,  Svend Havelund ,  Ulla Ribel-Madsen ,  Jeppe Sturis ,  Helle Naver ,  Morten Schlein ,  Svend Ludvigsen

IPC分类号： A61K47/22 ,  A61K47/18 ,  A61K47/02 ,  A61K38/28

CPC分类号： A61K38/28 ,  A61K9/0019 ,  A61K31/198 ,  A61K31/455 ,  A61K31/465 ,  A61K45/06 ,  A61K47/02 ,  A61K47/183 ,  A61K47/22 ,  A61K2300/00

摘要： Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid.

摘要翻译： 包含胰岛素化合物或两种或更多种胰岛素化合物，烟碱化合物和氨基酸的混合物的胰岛素制剂。

公开(公告)号：US10265385B2

公开(公告)日：2019-04-23

申请号：US16023328

申请日：2018-06-29

申请人： Novo Nordisk A/S

发明人： Mathias Norrman ,  Susanne Hostrup ,  Dorte Bjerre Steensgaard ,  Holger Martin Strauss ,  Rosa Rebecca Erritzoee Hansen ,  Svend Havelund ,  Morten Schlein ,  Jesper Soendergaard Pedersen

IPC分类号： A61K38/28 ,  A61P5/48 ,  A61K47/02 ,  A61K47/10

摘要： The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analog, and to the medical use of such compositions for basal insulin administration therapy.

公开(公告)号：US20180169190A1

公开(公告)日：2018-06-21

申请号：US15843016

申请日：2017-12-15

申请人： Novo Nordisk A/S

发明人： Mathias Norrman ,  Susanne Hostrup ,  Dorte Bjerre Steensgaard ,  Holger Martin Strauss ,  Rosa Rebecca Erritzoee Hansen ,  Svend Havelund ,  Morten Schlein ,  Jesper Soendergaard Pedersen

IPC分类号： A61K38/28 ,  A61K47/10 ,  A61P5/48 ,  A61K47/02

摘要： The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.

公开(公告)号：US20140349924A1

公开(公告)日：2014-11-27

申请号：US14336562

申请日：2014-07-21

申请人： Novo Nordisk A/S

发明人： Simon Bjerregaard Jensen ,  Svend Havelund ,  Florian A. Foeger

IPC分类号： A61K38/28 ,  A61K38/22

CPC分类号： A61K38/28 ,  A61K9/08 ,  A61K9/1688 ,  A61K9/19 ,  A61K38/22 ,  A61K47/10

摘要： The present invention relates to shelf stable non-aqueous pharmaceutical compositions, and to the use thereof in methods of treating diabetes and hyperglycaemia.

摘要翻译： 本发明涉及稳定的非水性药物组合物及其在治疗糖尿病和高血糖症的方法中的用途。

公开(公告)号：US20220249619A1

公开(公告)日：2022-08-11

申请号：US17626025

申请日：2020-07-10

申请人： Novo Nordisk A/S

发明人： Jeppe Sturis ,  Svend Havelund ,  Karen-Margrethe Pedersen

IPC分类号： A61K38/28 ,  A61K47/02 ,  A61K47/18 ,  A61K9/00 ,  A61K33/30 ,  A61P3/10 ,  A61K31/7084

摘要： The invention concerns a soluble insulin preparation comprising NϵB29-hexadecandioyl-γ-Glu-(desB30) human insulin in a concentration from 1800 nmol/ml to 4200 nmol/ml, Zinc ions in a concentration from 4.0 Zn/6Ins to 7.0 Zn/6Ins, Niacinamide in a concentration from 110 mM to 220 mM or treprostinil in a concentration from 0.02 μg/ml to 1 μg/ml, Citrate in a concentration from 6 mM to 40 mM, and pH in the range from 7.0 to 8.0. The invention further comprises a method for using the soluble insulin preparation for reducing the blood glucose level in a mammal and a process for preparing the soluble insulin preparations.

公开(公告)号：US20180303908A1

公开(公告)日：2018-10-25

申请号：US16023328

申请日：2018-06-29

申请人： Novo Nordisk A/S

发明人： Mathias Norrman ,  Susanne Hostrup ,  Dorte Bjerre Steensgaard ,  Holger Martin Strauss ,  Rosa Rebecca Erritzoee Hansen, Hansen ,  Svend Havelund ,  Morten Schlein ,  Jesper Soendergaard Pedersen

IPC分类号： A61K38/28 ,  A61K47/10 ,  A61P5/48 ,  A61K47/02

CPC分类号： A61K38/28 ,  A61K47/02 ,  A61K47/10 ,  A61P5/48

摘要： The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.